• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

VaxArray immunogenicity study published in Vaccine

Bioengineer by Bioengineer
April 26, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: InDevR, Inc.

BOULDER COLORADO (4/25/18) — "VaxArray for Hemagglutinin and Neuraminidase Potency Testing of Influenza Vaccines" describes a study designed to test the relationship between VaxArray-measured potency and vaccine-induced immunogenicity in mice. The study results represent a milestone in an industry-wide effort to qualify new potency assays for influenza vaccines.

For an A/H3N2 vaccine, the VaxArray neuraminidase (NA) potency assay was strongly correlated with enzymatic activity, highly sensitive to immunogenic forms of NA, and correlated with serum levels of NA inhibiting antibodies. In addition, the VaxArray hemagglutinin (HA) potency assay demonstrated equivalency to the current gold standard method and confirms the expected relationship to immunogenicity.

Although the authors acknowledge that more testing is needed, the consistent and predictive immunogenicity-potency relationships observed for VaxArray HA and NA support a conclusion that these assays can serve as a proxy for vaccine-induced immunogenicity and thereby are a measure the potency of the targeted antigen.

###

The effort was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Human Services (HHS), under Contract Number HHSN272201200005I. Additional resource support for serologic testing was provided by CBER FDA.

Find more information about the entire VaxArray vaccine potency testing platform at: https://indevr.com/products/vaxarray/

About InDevR

InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing diagnostics, vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit http://www.indevr.com or call 303-402-9100.

About Vaccine

Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society and The Japanese Society for Vaccinology and is published by Elsevier http://www.elsevier.com/locate/vaccine

HHS is not responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government or HHS.

MEDIA CONTACT
Shannon Rodriguez
InDevR
+1-303-402-9100
[email protected]

Media Contact

Shannon Rodriguez
[email protected]
303-402-9100

Home

Related Journal Article

http://dx.doi.org/10.1016/j.vaccine.2018.04.048

Share13Tweet8Share2ShareShareShare2

Related Posts

Revolutionizing Nine Hole Peg Test with Computer Vision

September 20, 2025

Linking Stigma and Diabetes Control in Adults

September 20, 2025

Designing Dual Inhibitors: Tricyclic Compounds Target AChE/MAO-B

September 20, 2025

Cyclic Stretch Enhances Chondrogenesis in Stem Cells

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Reticulocalbin-1: Biomarker and Therapy Target in RCC

Ag-Doped MnO2 Sea Urchin Structure Boosts Zinc Batteries

Revolutionizing Nine Hole Peg Test with Computer Vision

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.